Patents by Inventor BENJAMIN ANDERSCHOU HOLBECH JENSEN

BENJAMIN ANDERSCHOU HOLBECH JENSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911418
    Abstract: Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: February 27, 2024
    Assignees: Norges Miljo-Og Blovitenskapelige Universitet (NMBU), Sykehuset Ostfold HF, University of Copenhagen
    Inventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
  • Publication number: 20220305062
    Abstract: Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
    Type: Application
    Filed: April 12, 2022
    Publication date: September 29, 2022
    Inventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
  • Patent number: 11331349
    Abstract: The invention provides a method for the treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 17, 2022
    Assignees: NORGES MILJO-OG BIOVITENSKAPELIGE UNIVERSITET (NMBU), SYKEHUSET OSTFOLD HF, UNIVERSITY OF COPENHAGEN
    Inventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
  • Publication number: 20210393712
    Abstract: The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 23, 2021
    Applicant: Novozymes A/S
    Inventors: Nanna Ny Kristensen, Alexandra Mattern, Delphine Marie Anne Saulnier, Jeffrey Schultchen, Teis Jensen, Benjamin Anderschou Holbech Jensen
  • Publication number: 20200368292
    Abstract: The invention provides a method for the treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
    Type: Application
    Filed: August 2, 2018
    Publication date: November 26, 2020
    Inventors: TOR LEA, CHARLOTTE KLEIVELAND, KARSTEN KRISTIANSEN, BENJAMIN ANDERSCHOU HOLBECH JENSEN